ArticleAmerican journal of translational research2025
MiR-183-5p modulates inflammatory response and apoptosis in diabetic nephropathy by targeting the TTP.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo clarify the involvement of miR-183-5p, tristetraprolin (TTP), and inflammatory cytokines in Diabetic nephropathy (DN).
methodsThis retrospective study included 10 patients with DN, 10 patients with type 2 diabetes (T2DM) and 10 controls. Expression levels of miR-183-5p and TTP in T2DM patients and DN patients were detected, and the correlation between miR-183-5p, TTP, and inflammatory cytokines were analyzed. Renal tubular epithelial cells (HK-2) served as the cell model. The expression of TTP and cytokines in the cell cultures was detected using qRT-PCR or ELISA.
resultsmiR-183-5p promoted inflammation and apoptosis in the context of hyperglycemia. TTP was identified as the direct target of miR-183-5p. Elevated miR-183-5p expression in HK-2 cells resulted in increased inflammatory cytokine release and enhanced apoptosis. miR-183-5p inhibitors significantly reduced the levels of inflammatory cytokines in HK-2 cells.
conclusionsMiR-183-5p accelerates DN development through its action on TTP, thereby presenting a new therapeutic avenue for DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.